February 14, 2018 / 6:21 AM / in 6 days

BRIEF-Sensorion Announces Positive SENS-401 Phase 1 Clinical Trial Results

Feb 14 (Reuters) - SENSORION SA:

* ANNOUNCES NEW RESEARCH DATA‍​

* SENS-401 RESULTS SUGGEST DAILY DURATION OF DRUG EXPOSURE IS MORE IMPORTANT THAN MAXIMAL DOSE EXPOSURE

* 28-DAY SENS-401 TREATMENT PROVIDES BETTER HEARING OUTCOME THAN A 14-DAY TREATMENT

* PHASE 1 CLINICAL TRIAL SHOWS SENS-401 IS WELL TOLERATED

* TRIAL SHOWS SENS-401 PHARMACOKINETIC PROFILE CONFORMS TO EXPOSURES NEEDED FOR PRECLINICAL EFFICACY

* INTENDS TO START PHASE 2 STUDY WITH SENS-401 IN THIS INDICATION DURING H1 2018‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below